Plain-English translation of NCT06022146 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether given together three times per week for just one month can prevent tuberculosis as effectively as isoniazid and rifampicin given daily for three months. Both treatments are meant to stop latent TB infection (TB that's dormant in your body) from becoming active disease. The study focuses on teenagers and school staff who have been in close contact with someone who has active TB at school.
Millions of young people worldwide are infected with latent TB but never develop the active disease—yet many remain undiagnosed and at risk. This medication aims to provide a shorter, easier prevention option that could be completed faster and encourage more students and staff to finish their full treatment, ultimately reducing TB transmission in schools.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive either the one-month treatment ( three times per week) or the three-month treatment (isoniazid and rifampicin once daily), assigned randomly by your school group. You will take your assigned medication as instructed and be followed for two years with check-ins to make sure you stay healthy and don't develop active TB. The main goal is to see if the shorter treatment works just as well at preventing TB disease as the longer one.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China